Arcturus Therapeutics (Mfg)

San Diego, CA
Find alternatives to Arcturus Therapeutics (Mfg) for mRNA →
Hybrid — also manufactures internal programs
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
60.5
Signal Score
○ FDA Inspections ○ Clinical Trials ✓ SEC Filings (20) ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Arcturus Therapeutics (Mfg)

Signal Score
60.5/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
San Diego, CA
Modalities
mRNA
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Arcturus Therapeutics (Mfg)

Hybrid developer + CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesmRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 68.0
Parent company: Arcturus Therapeutics
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
20 SEC filings with industry mentions on record (shown, not scored)
SEC Filings20 with industry mentions (not scored)
Parent company: Arcturus Therapeutics
Financial assessment: 68.0/100
Capacity 53.0
1 manufacturing site: San Diego, CA
Modalities: mRNA
Capacity assessment: 53.0/100
Sites: San Diego, CA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: San Diego, CA
Modalities: mRNA
Capacity assessment: 53.0/100

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Financial Intelligence

8-K 2026-09-23 0 keyword mentions
"Item 7.01 Regulation FD Disclosure: On September 23, 2026, Arcturus Therapeutics Holdings Inc., a Delaware"
"Item 7.01 of this: Current Report on Form 8-K, the Presentation and the Release, shall not be deemed “filed” for purposes of Section 18 of the"
"Item 7.01 , and in the Presentation and the Release, shall not be: incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after"
8-K 2026-08-25 0 keyword mentions
"Item 7.01 of this: Current Report on Form 8-K, and the Presentation, shall not be deemed “filed” for purposes of Section 18 of the Securities"
"Item 7.01 , and in the Presentation, shall not be incorporated by reference: into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless"
10-Q 2026-08-06 4 keyword mentions
"(“Thermo Fisher”) and certain of Thermo Fisher’s affiliates to establish a strategic collaboration for the provision of contract development and manufacturing organization (“CDMO”) and contract research organization (“CRO”) services in connection with the development of ARCT-032, our investigational mRNA therapeutic for cystic fibrosis (“CF”)."
"Master Services Agreement The Thermo Fisher MSA establishes the framework under which Thermo Fisher and its affiliates will provide CRO and CDMO services to Arcturus from time to time pursuant to the Project Agreement and any additional individual project addendums."
"CRO services will be provided through PPD, Inc., Thermo Fisher’s affiliated contract research organization (“PPD”), and CDMO services will be provided through Thermo Fisher’s Pharma Services division."
8-K 2026-08-06 0 keyword mentions
"Item 2.02 of: this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of"
8-K 2026-07-02 3 keyword mentions
"(“ Thermo Fisher ”) and certain of Thermo Fisher’s affiliates to establish a strategic collaboration for the provision of contract development and manufacturing organization (“ CDMO ”) and contract research organization (“ CRO ”) services in connection with the development of ARCT-032, the Company’s investigational mRNA therapeutic for cystic fibrosis (“ CF ”)."
"The MSA establishes the framework under which Thermo Fisher and its affiliates will provide CRO and CDMO services to Arcturus from time to time pursuant to the Project Agreement and any additional individual project addendums."
"CRO services will be provided through PPD, Inc., Thermo Fisher’s affiliated contract research organization (“ PPD ”), and CDMO services will be provided through Thermo Fisher’s Pharma Services division."
8-K 2026-06-05 0 keyword mentions
"Item 5.07: Submission of Matters to a Vote of Security Holders."
10-Q 2026-05-07 0 keyword mentions
10-K 2026-03-03 14 keyword mentions
"Optimized conditions identified by these small-scale models are applied to the cGMP manufacturing processes."
"The success of CAR-T cells in immuno-oncology has led to a growing number of therapies utilizing other immune cell types engineered to express a variety of immunomodulatory molecules."
"With such collaborations, we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development & manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product."
8-K 2026-03-03 0 keyword mentions
8-K 2025-12-15 0 keyword mentions
10-Q 2025-11-12 0 keyword mentions
8-K 2025-11-10 0 keyword mentions
8-K 2025-10-22 0 keyword mentions
8-K 2025-09-26 0 keyword mentions
10-Q 2025-08-11 0 keyword mentions
10-Q 2025-05-12 0 keyword mentions
10-K 2025-03-06 17 keyword mentions
"Later, we published the results of Phase 3c part of the study, comparing the immunogenicity and efficacy of ARCT-154 and licensed adenoviral vector vaccine ChAdOx-1S, demonstrating higher immunogenicity and relative vaccine efficacy (19.8% (95% CI: 4.0–33.0)) of ARCT-154 compared to ChAdOx-1S ( https://pmc.ncbi.nlm.nih.gov/articles/PMC11585660/ )."
"Optimized conditions identified by these small-scale models are applied to the cGMP manufacturing processes."
"The success of CAR-T cells in immuno-oncology has led to a growing number of therapies utilizing other immune cell types engineered to express a variety of immunomodulatory molecules."
10-Q 2024-11-07 1 keyword mentions
"With such collaborations we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development & manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product."
10-Q 2024-08-05 1 keyword mentions
"With such collaborations we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development & manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product."
10-Q 2024-05-08 2 keyword mentions
"With such collaborations we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development & manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product."
"The increases were offset by a $3.5 million decrease in discovery technologies expenses, a $2.1 million decrease in COVID expenses primarily caused by fewer contract manufacturing costs and a $1.9 million decrease in OTC expenses."
Source: SEC EDGAR · Retrieved Nov 21, 2026

Frequently Asked Questions About Arcturus Therapeutics (Mfg)

What is Arcturus Therapeutics (Mfg)'s CDMO Signal Score?
Arcturus Therapeutics (Mfg) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Arcturus Therapeutics (Mfg) for a manufacturing program?
Use the free AI matchmaker to compare Arcturus Therapeutics (Mfg) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs →

Similar CDMOs

Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
Signal Score: 82.9
Recombinant Protein, Plasmid DNA, mRNA, Microbial Fermentation
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Signal Score: 73.6
mRNA, Gene Therapy, Cell Therapy, Lentiviral
TriLink BioTechnologies
San Diego, CA
Signal Score: 63.0
mRNA, Oligonucleotide
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein

Compare Arcturus Therapeutics (Mfg) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Arcturus Therapeutics (Mfg)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.